NCT02329184

Study Evaluating the Safety, Tolerability and Preliminary Pharmacokinetics and Pharmacodynamics of MYK-461

Safety, Tolerability, Preliminary Pharmacokinetics and Pharmacodynamics of Single Ascending Oral Doses of MYK-461 in Patient Volunteers With Hypertrophic Cardiomyopathy

• Status: Completed
• Phase: Phase 1
• Study type: Interventional
• Enrollment: 15 (actual)
• Sponsor: MyoKardia, Inc. · Industry
• Sex: All
• Age: 18 Years – 65 Years
• Healthy volunteers: Not accepted

Summary

The purpose of this study is to establish initial safety, tolerability, pharmacokinetics and pharmacodynamics of MYK-461 in human subjects. This is a sequential group, single ascending (oral) dose study in NYHA Class I, II, or III patient volunteers aged 18-65 years.

Conditions

• Hypertrophic Cardiomyopathy

Interventions

Type	Name	Description
DRUG	MYK-461

Timeline

• Start date: 2014-12-01
• Primary completion: 2016-03-01
• Completion: 2016-04-01
• First posted: 2014-12-31
• Last updated: 2016-09-14

Locations

7 sites across 1 country: United States